Cervomed INC 8-K filings

CervoMed announces positive results from its Phase 2b RewinD-LB trial extension, reports full year 2024 financial results, and plans for a Phase 3 trial in mid-2026.

CervoMed Inc. has made available information concerning its business, clinical studies, development plans, and financial position on its website.

CervoMed reports positive results from the extension phase of its Phase 2b RewinD-LB study, showing that a new batch of neflamapimod capsules led to increased drug concentrations and significant improvements in patients with dementia with Lewy bodies (DLB).

CervoMed announced topline results from the blinded phase of its RewinD-LB trial for neflamapimod in dementia with Lewy bodies, noting no significant difference between the drug and placebo, but highlighting potential with a new drug batch.

CervoMed's RewinD-LB Phase 2b clinical trial for neflamapimod in dementia with Lewy bodies did not meet its primary or secondary endpoints, leading to a pause in Phase 3 trial preparations.

CervoMed Inc. has made available an investor presentation on its website, covering business, clinical studies, development plans, and financial position.

CervoMed's investigational drug, neflamapimod, has been granted Orphan Drug Designation by the FDA for the treatment of frontotemporal dementia, highlighting its potential in addressing this rare condition.

CervoMed reported its Q3 2024 financial results, received the Prix Galien USA 2024 Best Startup award, and appointed two new senior leaders.

CervoMed announced key findings from presentations at the Clinical Trials on Alzheimer's Disease Conference, showcasing the potential of neflamapimod for treating dementia with Lewy bodies.

CervoMed will present detailed safety and efficacy results from its RewinD-LB Phase 2b clinical trial of neflamapimod at the International Lewy Body Dementia Conference in January 2025.

CervoMed has announced the completion of the last patient visit in its Phase 2b RewinD-LB trial for neflamapimod, a potential treatment for early-stage dementia with Lewy bodies, with topline data expected in December 2024.

CervoMed Inc. has terminated its At-The-Market Sales Agreement with BTIG, LLC, effective October 11, 2024, without any penalties and having not sold any shares under the agreement.

CervoMed will present plasma biomarker data from its Phase 2a study and baseline data from its Phase 2b study of neflamapimod for dementia with Lewy bodies at the upcoming CTAD conference.

CervoMed announced the completion of enrollment in its Phase 2b RewinD-LB clinical trial for early-stage dementia with Lewy bodies and reported second quarter 2024 financial results, including a significant increase in cash reserves.

CervoMed presented positive plasma biomarker data from its AscenD-LB Phase 2a trial at the Alzheimer's Association International Conference, showing neflamapimod's impact on the underlying disease process in patients with dementia with Lewy bodies.

CervoMed Inc. hosted a virtual key opinion leader event on July 23, 2024, focusing on neflamapimod for treating dementia with Lewy bodies, with presentation materials available on their website.

CervoMed will host a virtual key opinion leader event on July 23, 2024, to discuss neflamapimod for the treatment of dementia with Lewy bodies, following the full enrollment of its Phase 2b RewinD-LB trial.

CervoMed has finished enrolling patients in its Phase 2b RewinD-LB clinical trial for neflamapimod, a potential treatment for dementia with Lewy bodies, with topline data anticipated in December 2024.

CervoMed has appointed William Elder as its new Chief Financial Officer, effective June 1, 2024, while former CFO William Tanner transitions to a consulting role.

CervoMed announced its first quarter 2024 financial results, highlighted by a $149.4 million private placement and progress in its Phase 2b clinical trial for neflamapimod.

CervoMed Inc. has made available a corporate presentation on its website and disclosed the number of outstanding shares as of April 22, 2024.

CervoMed announced a significant private placement to fund its operations through 2025 and provided updates on its clinical trial for neflamapimod in dementia with Lewy bodies.

CervoMed Inc. has made available a corporate presentation on its website, covering business, clinical studies, development plans, and financial position.

CervoMed has announced a private placement expected to raise up to $149.4 million to fund research and development of its clinical-stage product candidate.

CervoMed Inc. has announced June 14, 2024, as the date for its annual stockholders meeting and set April 1, 2024, as the deadline for shareholder proposals.

CervoMed presented biomarker data from its Phase 2a trial showing neflamapimod significantly reduced a key protein marker in patients with dementia with Lewy bodies, and also presented preclinical data supporting its potential in tau-related diseases.

CervoMed Inc. amended a pre-funded warrant held by the Joshua S. Boger 2021 Trust, removing a restriction on ownership and allowing the trust to fully exercise the warrant.

CervoMed appoints Joshua Boger, founder of Vertex Pharmaceuticals, as Board Chair and announces participation in an investor conference, while remaining on track with its Phase 2b clinical trial for neflamapimod.

CervoMed Inc. has formalized new employment agreements with its CEO, COO, and Senior VP of Clinical Development, outlining their compensation and severance terms.